Aktis Oncology has closed a series A extension round to the tune of $84 million, with big pharmas Merck Novartis and BMS joining to expand the biotech’s bandwidth for developing radiopharmaceutical cancer treatments.

More than a month after axing 94 employees, PACT Pharma is culling its lead asset and diverting 54 of the laid-off employees to a new business development venture that's yet to be named.

3T Biosciences has stepped out of the shadows equipped with $40 million in series A cash and a platform designed to address two major challenges in T-cell-receptor-based therapeutics. Armed with the cash, the West Coast biotech plans to advance a pipeline featuring development-stage TCR-T cell assets.

After nine years on the market and winning 11 FDA approvals, Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod. This one is for chronic graft-versus-host disease (cGVHD) and gives children ages 1 to 11 their first treatment option for the life-threatening disorder. The FDA first signed off on Imbruvica’s use for those 12 and older with cGVHD in 2017.

Open Orphan subsidiary hVIVO has inked a 10.4 million pound sterling ($12.3 million) deal with a large, unnamed pharmaceutical company to produce a novel batch of H1N1 influenza challenge virus.

Less than a year into a strategic review, Novartis has decided to spin off its generics unit Sandoz. The separation will allow both companies to pursue different capital allocation strategies, CEO Vas Narasimhan, M.D., said.

The AI system analyzes a sleeping person's breathing patterns for some of the earliest signs of Parkinson’s or to note changes in the severity of the disease over time.

Worldwide Clinical Trials, a North Carolina-based CRO, is expanding its services with a new 15,000-square-foot bioanalytical laboratory at its Austin, Texas, location.

Three years after it began piloting a primary care service for its employees that blended telehealth and in-person medical services, Amazon plans to shutter its Amazon Care service for employers.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.